Comparative toxicity assessment between generic salbutamol sulphate inhaler containing hydrofluoroalkane and Ventolin Evohaler


Salbutamol is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm such as asthma and chronic obstructive pulmonary disease (COPD). It is mostly taken through an inhaler device. The comparative toxicity assessment between two salbutamol sulfate preparations containing hydrofluoroalkane (HFA) metered dose inhalers with 100 μg per puff was evaluated in selected patients with asthma and COPD after prescribing. An open label, non-randomized, non-interventional observational study was designed. A large cohort of patients with asthma or related respiratory disorder of the general population from Dhaka and Chittagong of Bangladesh were recruited and treated with prescribed generic preparation Azmasol inhaler and brand preparation Ventolin Evohaler. Total 508 patients with asthma and minor obstructive airway disease were selected by the general medical practitioners in Bangladesh those who visited out patient consultation center in hospitals and physicians’ chambers and reported any adverse side effects of inhaled medications. There were no significant differences between the metered dose generic preparation Azmasol inhaler and Ventolon Evohaler among the patients treated with the medicines in asthma and related respiratory diseases in terms of adverse effects like immune system problem,dizziness,tremor,headache,nervousness,diarrhea,nausea,vomiting,heartburn,palpitation,skin rash,hypertension and taste feeling. It is concluded that Azmasol Inhaler, the generic salbutamol sulphate metered dose preparation containing HFA was as safe as the Ventolin Evohaler,a salbutamol sulfate brand preparation containing HFA when given to the patients in primary care after their physicians’ visits. Both the preparations have shown the similar safety profiles after regular use.

Share and Cite:

Roy, S. , Jalil, M. , Tithi, N. , Saha, S. , Raihan, S. , Chanda, U. , Ghosh, C. and Bachar, S. (2013) Comparative toxicity assessment between generic salbutamol sulphate inhaler containing hydrofluoroalkane and Ventolin Evohaler. Open Journal of Preventive Medicine, 3, 275-279. doi: 10.4236/ojpm.2013.33037.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Association of the British Pharmaceutical Industry (1996) Guidelines for company sponsored safety assessment of marketed medicines (SAMM). In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. Datapharm Publications, London.
[2] Rawlins, M.D. and Jefferys, D.B. (1991) Study of United Kingdom product license applications containing new active substances, 1987-1989. British Medical Journal, 302, 223-225. doi:10.1136/bmj.302.6770.223
[3] Dockhorn, R., Vanden Burgt, J.A., Ekholm, B.P., Donnell, D. and Cullen, M.T. (1995) Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. Journal of Allergy and Clinical Immunology, 96, 50-56. doi:10.1016/S0091-6749(95)70032-3
[4] Kleerup, E.C., Tashkin, D.P., Cline, A.C. and Ekholm, B.P. (1996) Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered dose inhaler in patients with asthma. Chest, 109, 702-707. doi:10.1378/chest.109.3.702
[5] Tinkelman, D.G., Bleecker, E.R., Ramsdell, J., Ekholm, B.P., Klinger, N.M., Colice, G.L. and Slade, H.B. (1998) Proventil HFA and Ventolin have similar safety profiles during regular use. Chest, 113, 290-296. doi:10.1378/chest.113.2.290
[6] Bleecker, E.R., Tinkelman, D.G., Ramsdell, J., Ekholm, B.P., Klinger, N.M., Colice, G.L. and Slade, H.B. (1998) Proventil HFA provides bronchodilation comparable to Ventolin over 12 weeks of regular use in asthmatics. Chest, 113, 283-289. doi:10.1378/chest.113.2.283
[7] Craig-McFeely, P.M., Wilton, L.V., Soriano, J.B., Maier, W.C. and Shakir, S.A. (2003) Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. International Journal of Clinical Pharmacology, Therapy, & Toxicology, 41, 67-76.
[8] Report of the Auditor General of Canada to the House of Commons (2011) Regulating pharmaceutical drugs— Health Canada. Minister of Public Works and Government Services, 26.
[9] Ayres, J.G., Frost, C.D., Holmes, W.F., Williams, D.R.R. and Ward, S.M. (1998) Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the safety assessment of marketed medicines guidelines. British Medical Journal, 317, 926-930. doi:10.1136/bmj.317.7163.926
[11] European Agency for the Evaluation of Medicinal Products (1995) Guideline for postmarketing surveillance studies for metered dose inhalers with new propellants. EAEMP, London.
[12] Hendeles, L., Colice, G.L. and Meyer, R.J. (2007) Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. New England Journal of Medicine, 356, 1344-1351. doi:10.1056/NEJMra050380

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.